Intracoronary thrombosis plays an important role in the pathogenesis of acute coronary syndrome. It occurs due to a rupture of an atherosclerotic plaque, which may be spontaneous, as in the case of acute coronary syndrome, or due to procedures such as percutaneous intervention (PCI). Atherosclerotic plaque rupture causes exposure of thrombogenic subendothelial components and initiates platelet aggregation, which then initiates the coagulation cascade. In stable angina, the formation of platelet thrombus is the most important tiling to occur on plaque progressiveness as a result of rupture and episodic formation of thrombi.' Arterial thrombi contain many platelets. Anti-platelet agents are greatly beneficial in acute and chronic coronary heart disease. This paper discusses the use of anti-platelet agents in coronary heart disease.